Istituti Clinici Scientifici Maugeri SpA   Report issue

Academic/Hospital Phase 2
Founded: Turin Italy (1965)

Organization Overview

First Clinical Trial
2018
NCT04459091
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

ICS Maugeri care and Research Institute, Pavia, Italy | Istituti Clinici Scientifici Maugeri | Istituti Clinici Scientifici Maugeri, IRCCS | Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy | Istituti Clinici Scientifici Maugeri SpA

Active Ingredients

Drugs in Phase 2 Trials (1)

pembrolizumab (keytruda) (2 trials)

Drugs in Other Trials (2)

essential amino acids (1 trial)

oxygen (1 trial)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3